Amgen: Q4 beats consensus

(CercleFinance.com) - On Tuesday evening Amgen reported Q4 2018 adjusted EPS that is up 18% at 3.
42 dollars, i.e. about fifteen cents higher than the consensus, while its adjusted operating profit was up 6% at 2.7 billion dollars.

The biopharmaceutical company's revenues rose by 7% to 6.2 billion dollars, with the sales of recently launched products, including Repatha, Prolia, Kyprolis and Xgeva, reporting double-digit growth.

Therefore, having reported adjusted EPS of 14.40 dollars and revenues of 23.7 billion dollars over FY 2018, Amgen expects a target EPS range of 13.10 dollars to 14.30 dollars, with revenues of 21.8 billion dollars to 22.9 billion dollars.


Copyright (c) 2019 CercleFinance.com. All rights reserved.